Technical Advances to Accelerate Modular Type I Polyketide Synthase Engineering towards a Retro-biosynthetic Platform

Pang, Bo; Valencia, Luis E.; Wang, Jessica; Wan, Yao; Lal, Ravi; Zargar, Amin; Keasling, Jay D.

Published in:
Biotechnology and Bioprocess Engineering

Link to article, DOI:
[10.1007/s12257-019-0083-9](https://doi.org/10.1007/s12257-019-0083-9)

Publication date:
2019

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Pang, B., Valencia, L. E., Wang, J., Wan, Y., Lal, R., Zargar, A., & Keasling, J. D. (2019). Technical Advances to Accelerate Modular Type I Polyketide Synthase Engineering towards a Retro-biosynthetic Platform. *Biotechnology and Bioprocess Engineering*, 24(3), 413-423. <https://doi.org/10.1007/s12257-019-0083-9>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Lawrence Berkeley National Laboratory

Recent Work

Title

Technical Advances to Accelerate Modular Type I Polyketide Synthase Engineering towards a Retro-biosynthetic Platform

Permalink

<https://escholarship.org/uc/item/9nq6g6dz>

Journal

Biotechnology and Bioprocess Engineering, 24(3)

ISSN

1226-8372

Authors

Pang, B
Valencia, LE
Wang, J
et al.

Publication Date

2019-06-01

DOI

10.1007/s12257-019-0083-9

Peer reviewed

Technical advances to accelerate modular type I polyketide synthase engineering towards a retro-biosynthetic platform

Bo Pang^{# 1,2,3}, Luis E. Valencia^{# 1,3,4}, Jessica Wang¹, Yao Wan^{1,2,3}, Ravi Lal¹, Amin Zargar^{1,3}, Jay D. Keasling^{1,2,3,4,5,6,7 *}

¹ Joint BioEnergy Institute, Emeryville, CA 94608, USA

² QB3 Institute, University of California, Berkeley, CA 94720, USA

³ Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

⁴ Department of Bioengineering, University of California, Berkeley, CA 94720, USA

⁵ Department of Chemical & Biomolecular Engineering, University of California, Berkeley, Berkeley, CA 94720, USA

⁶ Novo Nordisk Foundation Center for Biosustainability, Technical University Denmark, DK2970-Horsholm, Denmark

⁷ Synthetic Biochemistry Center, Institute for Synthetic Biology, Shenzhen Institutes for Advanced Technologies, Shenzhen, Guangdong 518055, China

* Correspondence: Dr. Jay D. Keasling, Joint BioEnergy Institute, 5885 Hollis St. 4th floor, Emeryville, CA 94608, USA; Phone: 510-486-2630, E-mail: jdkeasling@lbl.gov

[#] Equal contribution.

25 **Abstract**

26 Modular type I polyketide synthases (PKSs) are multifunctional proteins that are comprised of
27 individual domains organized into modules. These modules act together to assemble complex
28 polyketides from acyl-CoA substrates in a linear fashion. This assembly-line enzymology makes
29 engineered PKSs a potential retro-biosynthetic platform to produce fuels, commodity chemicals,
30 speciality chemicals, and pharmaceuticals in various host microorganisms, including bacteria and fungi.
31 However, the realization of this potential is restricted by practical difficulties in strain engineering,
32 protein overexpression, and titer/yield optimization. These challenges are becoming more possible to
33 overcome due to technical advances in PKS design, engineered heterologous hosts, DNA synthesis and
34 assembly, PKS heterologous expression, and analytical methodology. In this review, we highlight these
35 technical advances in PKS engineering and provide practical considerations thereof.

36 **Keywords**

37 polyketide synthase, retro-biosynthetic analysis, protein engineering, heterologous expression,
38 biofuels, bioproducts

39 1. Introduction

40 Retrobiosynthesis, an approach to design *de novo* biosynthetic pathways, has enabled the
41 production of various useful chemicals, including biofuels [1] and drugs [2]. In this approach, design
42 starts from the target molecule and proceeds backwards to precursors by considering stepwise
43 biochemical reactions. Modular type I polyketide synthases (PKSs) have the potential to be a versatile
44 retro-biosynthetic platform for its collinear and modular biosynthetic logic. Native PKSs catalyze the
45 formation of carbon-carbon bonds in an assembly-line manner to synthesize the scaffolds of complex
46 natural products, such as macrolides (*e.g.* 6-deoxyerythronolide B) [3], polyenes (*e.g.* α -lipomycin) [4],
47 and polyethers (*e.g.* salinomycin) [5]. In this biosynthetic process, each module of a PKS catalyzes a
48 two-carbon elongation followed by potential reductions. During elongation, the acyltransferase (AT)
49 domain loads a specific malonyl-CoA analog onto the phosphopantetheinyl group of the acyl-carrier
50 protein (ACP) domain. This phosphopantetheinyl group is derived from the essential post modification
51 of PKS via phosphopantetheinyl transferases (PPtases). After loading, the ketosynthase (KS) domain,
52 which is primed with an acyl group (a starter acyl group or an acyl chain formed in the previous module),
53 catalyzes a Claisen condensation to fuse the acyl group with the decarboxylated malonyl unit. After
54 elongation, if present, the ketoreductase (KR) domain stereoselectivity reduces the β -ketone to a
55 hydroxyl group. The dehydratase (DH) domain can then catalyze a dehydration, resulting in the loss of
56 this hydroxyl group to form an α - β double bond. Finally, the enoylreductase (ER) domain can reduce
57 this α - β double bond to form a saturated bond. The oxidation state of the β -carbon depends on the
58 presence of reductive domains in each module. Following rounds of elongation and reduction, the acyl-
59 chain is released by a thioesterase (TE) domain by cyclization to form a macrolactone or hydrolysis to
60 form a linear product. The collinearity of the PKS biosynthetic process results in a diversity of products
61 due to different AT substrate specificities and varying degrees of reductions in each module, and the
62 different module organizations (**Fig. 1**).

63
64 Many fundamental studies used engineered PKSs as a retro-biosynthetic platform by
65 conducting domain modifications, domain swaps, and module rearrangements; these results have been

extensively reviewed elsewhere [6–9]. These studies indicated that there is still a large gap between the promise of PKS engineering and reality, especially for constructing novel multi-module PKSs. Hence, compared to complex natural products, commodity chemicals or biofuels bearing simple structures are more realistic targets for PKS engineering [8]. The production of these targets only requires connecting a limited number of PKS modules (usually ≤ 2). However, even for these simple targets, unique challenges emerge when engineering PKSs to produce compounds *in vivo*. Besides the fundamentally mechanistic understanding of PKS biosynthesis, these challenges stem from the practical difficulties in novel PKS design, host selection, large DNA fragment synthesis and assembly, target production, and product detection (**Fig. 1**). In this review, we highlight the state-of-the-art technical advances that deal with these challenges and provide practical considerations for PKS engineering.

2. PKS design

To determine a target molecule for production using PKSs, both economic and technical considerations must be evaluated. First, the candidate should be assessed for cost and energy efficiency. Next, retro-biosynthetic analysis can be used to evaluate the feasibility for the candidate molecule to be made through PKS mechanisms. Once a candidate is established to be a feasible target molecule, an initial biosynthetic pathway may be designed using software tools (**Fig. 2**).

Deciding on a target molecule depends on economic feasibility, which reduces to evaluating the value of the candidate against the cost of its production. An estimate of the candidate's monetary value can be established based on existing commercial value, if known. Otherwise, the value should be estimated according to the candidate's potential applications or molecules with similar functions [10]. To determine production cost, a techno-economic analysis that considers molecular precursors, energy requirements, and production time may be performed [11]. Finally, it is important to consider if the target molecule can be produced in a more practical or economically favorable means through other biosynthetic pathways. While PKSs have recently been engineered to produce short-chain ketones, potential gasoline blending agents, from plant biomass at titers of 1 g/L [12], fatty acid and isoprenoid

92 synthesis are currently more established production pathways with higher yields [13]. This holistic
93 economic analysis of the target molecule can guide the extent of engineering efforts required for
94 production.

95
96 Once established as economically feasible, a retro-biosynthetic analysis can determine a
97 possible pathway for attaining the compound. In this process, the candidate should be deconstructed by
98 carbon-carbon bond breaking according to PKS biosynthetic logic. Engineered PKSs modular nature
99 can be leveraged to programmatically produce non-natural compounds. As such, extensive research has
100 been performed to understand the rules concerning domain swapping to control chain extender unit
101 selection at the acyltransferase (AT) domain and the degree of β -carbonyl reduction by the
102 ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER) [14–16]. For example, the swapping
103 of non-native ATs has been successfully achieved to switch from methyl-malonyl to malonyl extension
104 [17], and research has been conducted to discover AT's that accept extender units with exotic sidechains
105 (phenyl, allyl, etc.) [18, 19]. The principles of domain swapping in PKSs are maturing, and there is a
106 wealth of information to determine viability for novel PKS products [9, 20]. In parallel, considerable
107 progress has been made to engineer PKS domains with more traditional protein engineering methods
108 (*e.g.* mutagenesis) [21]. With the expanding research on the engineering possibilities of PKSs, the range
109 of molecules that are accessible through PKS biosynthetic pathways is continuously growing.

110
111 With a viable target molecule determined, software enables the rapid identification of natural
112 PKS domain candidates to be combined into a suitable catalytic system. Most recently, the free, online
113 software package ClusterCAD [22] has been developed for *in silico* engineering of PKS pathways to
114 achieve synthesis of a specified product. ClusterCAD semi-quantitatively determines the similarity of
115 the target molecule to the native substrates of an annotated database of biosynthetic gene clusters. Users
116 may additionally specify design constraints, such as native substrate size similarity or AT extender
117 selectivity, to narrow the number of possible routes to the product. The software then proposes
118 biosynthetic pathways that combine components from multiple PKSs that meet the design criteria.
119 ClusterCAD is also just one of the many available *in silico* tools that help guide the engineering process.

120 The identification of biosynthetic loci for every known secondary metabolite class [23], the structure-
121 based sequence analysis of PKSs [24], and a crowd-sourced database of microbial PKS and NRPS gene
122 clusters [25] are all accessible from present software tools. Despite such advances in our understanding
123 of PKS engineering, not all design rules for these enzymatic systems have yet been elucidated. As a
124 result, an experimental, combinatorial approach to produce the output PKS systems is often still the
125 most effective method for successful PKS engineering.

3. Host selection

The growth properties of the host organism are important to take into account when selecting a heterologous host for PKS production. Many natural polyketide producing microbes are not culturable in laboratory conditions [26] or grow very slowly in laboratory conditions as is the case with lichen [27] and thus are not suitable hosts for heterologous expression. Bacteria from the genus *Streptomyces* are common heterologous hosts for PKSs due to their status as prominent PKS producers but they can frequently present issues for industrial scale-up including slow growth and the tendency to form mycelial clumps [28], the latter of which has been shown in some cases to be important in the activation of biosynthetic gene clusters [29]. Despite that, *Streptomyces* continue to be one of the most popular industrial heterologous hosts for polyketide products and major efforts have been put in place to engineer strains that do not form clumps and grow quickly [30]. Another growth property of interest includes the carbon and energy sources used by the heterologous host. Heterologous hosts such as *Pseudomonas putida* which consume a wide variety of lignin compounds as a carbon source [31] or the cyanobacterium *Synechococcus elongatus*, which can use light as an energy source and CO₂ as a carbon source [32] have been adapted for the production of PKSs (**Table 1**).

The availability of genetic tools for a particular host is of great aid to the task of genetically engineering a host to heterologously produce polyketides. Most common heterologous hosts have well developed methods for transformation, conjugation, or transduction of vectors. Of particular importance for controlling expression levels heterologously is a comprehensive list of compatible promoters and RBSs (**Fig. 3(A)**). These are well known for classic heterologous hosts like *E. coli* [33] and there have been successful efforts to develop promoter-RBS libraries for *Streptomyces* [34]. Ultimately, genomic integration of engineered gene clusters is desired in industrial heterologous host strains as it eliminates the need for selection pressures such as antibiotics and provides a more stable and consistent expression of genes [35]. Tools for genomic integration—such as site-specific integrases, homologous recombination-based integration vectors, and CRISPR-Cas9—are widely available for common hosts like *E. coli* and have also been adapted for *Streptomyces* [36–38]. As these tools continue to be

developed for *Streptomyces* and other suitable PKS hosts the ability to heterologously produce PKSs will continue to improve.

When selecting a host for heterologous expression one must consider the existing metabolic infrastructure to ensure that the host contains all the precursors and tailoring enzymes needed to produce the desired polyketide. Among the most important things to consider is the expression of a compatible PPTase [39] (**Fig. 3(B)**). As mentioned above, PPTases are responsible for activating ACPs by modifying the active site serine with a phosphopantetheinyl moiety. To ensure the heterologous host can phosphopantetheinylate the engineered PKS in question it is important to ensure the host expresses an appropriate PPTase. While many natural type I PKS producers such as *Streptomyces* have native PPTases, many common hosts do not and a PPTase must be heterologously expressed. One of the most common PPTases used in heterologous PKS expression is Sfp from *Bacillus subtilis* because it is capable of phosphopantetheinylating a wide variety of type I PKS and NRPS carrier proteins [40, 41]. However, Sfp may not be active on certain PKSs [42], thus it is important to check for phosphopantetheinylation via proteomics methods [43]. Another important prerequisite is the availability of precursors such as extender units and starter acyl-CoAs. The most common extender units used by PKSs are malonyl-CoA and methylmalonyl-CoA [44] although there do exist a variety of rare extender units as seen in the biosynthesis of zwittermycin [45], chlorizidine [46], or unnatural extender units [47] that can be incorporated by engineered PKSs (**Fig. 3(C)**). While all organisms produce malonyl-CoA for fatty acid synthesis the ability to produce methylmalonyl-CoA is absent from many common hosts such as *E. coli* and *S. cerevisiae*. This challenge was overcome in *E. coli* by the development of the K207-3 strain which has both Sfp and a propionyl-CoA carboxylase present to produce intracellular methylmalonyl-CoA [48]. Ultimately a researcher must determine what precursors and tailoring enzymes are necessary for the production of their desired molecule and must take steps to either engineer the heterologous host to produce these precursors or find a heterologous host that naturally produces these precursors and tailoring enzymes.

The stability and toxicity of the target molecule in the heterologous host must be evaluated. It is possible for the target molecule to be toxic to the host, therefore it is important to do a growth inhibition assay if a sample of the target molecule is available. Additionally, it is possible for the target molecule to be consumed as a carbon source by the host organism. This can be determined by growing the organism on the target molecule as a sole carbon source if possible. Finally, it is possible for the target molecule to be modified or unstable in the cell and this can be detected by incubating the target molecule in cell lysate before extraction and analysis.

4. DNA synthesis and assembly

After the target PKS organization and host are determined during the design stage, the careful consideration of the strategy for DNA synthesis and assembly of PKS genes are needed in the build stage (**Fig. 4**). To expedite the whole engineering process, automation of the steps in the build stage is preferable, although some challenges exist.

PKSs are typically encoded by a series of genes clustered in the genome of the producing organisms [49]. Thus, the cloning and expression of PKSs can be achieved by acquiring the genomic DNA (gDNA) harboring the entire cluster from a gDNA library construction. In addition to the phage-mediated homologous recombination-based methods [50], transformation-associated recombination (TAR)-based techniques have been developed to capture large biosynthetic gene clusters from environmental DNA or gDNA samples. These techniques utilize the native *in vivo* homologous recombination of budding yeast *Saccharomyces cerevisiae*, which occurs in much higher frequency compared to ligation or non-homologous end joining methods [51]. On the other hand, *in vitro* homology-based methods such as Gibson assembly and sequence- and ligation-independent cloning (SLIC) methods are advantageous over *in vivo* methods in the turnaround time, although the construct size is typically smaller.

If the PKS genes are heterologously expressed and require DNA refactoring like codon optimization, it is most likely that *de novo* DNA synthesis is needed. Although the trends of price per base for DNA sequencing and column-based oligonucleotide synthesis seem to have reached plateaus in recent years, the cost for gene synthesis continues to decrease [52]. As an alternative to outsourcing DNA synthesis, array-based gene synthesis may be carried in house, followed by error correction and verification [53]. In addition, enzymatic *de novo* synthesis of oligonucleotides with terminal deoxynucleotidyl transferase (TdT)-deoxynucleotide triphosphates (dNTPs) conjugates may serve as a promising basis for enzymatic oligonucleotide synthesizer [54]. Online tools such as JBEI ICE public registry [55] and SynBioHub [56] may facilitate users to search and share the designs of DNA parts.

Because PKS genes are typically modular, the modules are usually exchanged during PKS engineering in combination with various promoters, terminators, ribosome-binding sites (RBSs), linker domains, and other parts. If DNA cloning is high-fidelity, sequencing the individual parts may be avoided to reduce cost and effort and save time. Different parts could then be assembled by several methods including yeast assembly [57], Gibson assembly [58], and Golden Gate assembly [59]. In the case of PKS gene construction, although yeast assembly takes a few days, it has the advantages of generating large final gene constructs and promoting recombinational joining of unrelated DNA fragments with the aid of “stitching oligonucleotides”, compared with *in vitro* methods [60]. The construction of shuttle vectors that allow amplification, replication, and expression in *S. cerevisiae*, *E. coli* and the selected host would greatly facilitate this process, as well as the development of automation method such as high-throughput transformation of *S. cerevisiae* using liquid handling robots [61].

5. Production and analysis

The introduction of the assembled PKS genes into the selected host yields the candidate strain, which needs the appropriate conditions to produce the target molecules. After production, analytical methods allow researchers to assess the production of the desired product and/or possible shunt products

to evaluate the performance of the engineered PKS. Finally, troubleshooting and optimization can be facilitated by detection of intermediates and high throughput screens.

A major consideration in the production stage is the selection of a growth medium. A well-selected medium facilitates the strain's growth and PKS biosynthesis [62, 63] and ultimately increases the chance of detecting the final product [64], considering most engineered PKSs result in a decreased production [6, 8]. The media preferences for the PKS production vary from host to host. For common heterologous hosts the media selection can be straightforward since the media for these organisms are widely used and commercially available. Additionally, PKS production in these organisms is clear, as the precursor biosynthetic genes and PPtase gene are usually under the control of strong constitutive promoters [48, 65, 66]. Hence, rich media are usually the first choice for these hosts. Examples include LB medium used to produce lactones [67, 68] and short chain ketones [17] by engineered PKSs in *E. coli*, while YPD medium was used to produce lactones by engineered PKSs in *Saccharomyces cerevisiae* [65]. However, as most native PKS producers are not model organisms, the media selection could be challenging when these organisms are chosen as hosts. Rich media usually suitable for cell growth may not be suitable for PKS production in these hosts, since these hosts typically produce their native PKSs under nutritional deficiencies [69]. Therefore, for the PKS production in these non-model hosts, production mediums screens are usually required to produce the desired molecules [64, 70] (Table 1).

Once production of the target molecule is confirmed, media optimization is required to maximize the yield and reduce cost. This optimization is crucial for low-value commodity chemicals/biofuels production. In this process, carbon source, nitrogen source, phosphate, and other nutrients are carefully adjusted via a one-factor-at-a-time method or statistical method [71]. In the case of short chain ketone production by an engineered PKS in *S. albus*, when the carbon source was supplemented by the plant-biomass hydrolysates the product titer increased more than four-fold and further titer increases were achieved by feeding specific acyl-CoA precursors [12]. Aside from

traditional methods, recently developed machine learning algorithms have great potential to accelerate the media optimization process [72].

Researchers receive feedback regarding the functionality of their engineered PKS when analytical methods are used to detect reaction products. Gas/liquid chromatography coupled to mass spectrometry (GC/LC-MS)-based methods are usually the first choice for analysis [12, 73, 74] because of their low detection limit for commodity chemicals and biofuels. However, these methods only detect released molecules and leave the PKS biosynthetic pathway a black box. Engineered PKSs frequently fail to produce any free products *in vivo* in the first Design-Build-Test-Learn (DBTL) cycle. Thus, other analytic approaches are needed to debug these failed PKSs for the next DBTL cycle. Transcriptome [75] and proteomics [76] analysis are well developed to detect the expression of PKSs. Plant ejection methods are designed to detect on-line PKS intermediates [43]; this method was used to optimize an adipic acid producing PKS *in vitro* [74] (**Fig. 5(B)**). Together, these analytical methods can be used effectively to detect the production of target molecules or help troubleshoot malfunctioning modules.

Aside from these ‘rational’ approaches, high throughput screening/selection is another possible route to create a functional PKS *in vivo*. With well-developed mutagenesis methods, generating a big mutant library is feasible for a specific PKS [77]. The methods used to select or screen for an improved mutant result in the largest bottleneck in a high throughput approach. Screening via GC/LC-MS systems is a possibility [78], however, despite the availability of high throughput GC/LC-MS systems that have reached the speed of several seconds per sample [79], it is still ineffective when the size of mutagenesis library becomes large ($>10^{10}$). High throughput detection could be achieved by tying the production of the target molecule with a detectable signal or with the viability of the hosts [80]. For most compounds lacking bioactivity or a chromophore, biosensors are usually required to perform the connections. Although to our knowledge there are no reported cases of a biosensor being coupled with type I PKS production *in vivo*, some biosensors are reported to detect chemicals that are made or can be possibly made by engineered PKSs, such as diacids [74, 81], lactams [82–84], and pyrones [85, 86]. These compounds are promising targets for high throughput PKS engineering (**Fig. 5(B)**).

286

287 **6. Conclusions**

288

289 Currently, engineered PKSs can produce several products that are not naturally occurring
290 products in microorganisms. These accomplishments benefit from an expanded understanding of type
291 I modular PKS biosynthetic mechanisms, as well as technical advances summarized here. Similar
292 advances will continue to emerge and promote PKS engineering to be a reliable retro-synthetic platform
293 for the production of commodity chemicals and biofuels. We speculate that over the next few decades,
294 an automatic solution to produce new chemicals by engineered PKS will be available. This technology
295 will include an automatic retro-synthesis software, super hosts for PKS production, automatic DNA
296 synthesis and assembly platforms, and high-throughput production and analytical methods. This has
297 begun to be realized since these technologies have been developed in related fields such as PKS derived
298 natural products discovery [80, 87–89]. By harnessing these advances in PKS engineering and synthetic
299 biology technologies, we will be able to engineer PKS to access an extensive chemical space.

300

301 **Acknowledgements**

302 This work was part of the DOE Joint BioEnergy Institute (<https://www.jbei.org>) supported by the U. S.
303 Department of Energy, Office of Science, Office of Biological and Environmental Research.
304 Department of Energy, Energy Efficiency and Renewable Energy, Bioenergy Technologies Office,
305 through contract DE-AC02-05CH11231 between Lawrence Berkeley National Laboratory and the U.
306 S. Department of Energy. This work was also funded by the National Institute of Health
307 (F32GM125179).

308 **Conflict of interest**

309 J.D.K. has financial interests in Amyris, Lygos, Constructive Biology, Demetrix, Napigen, Maple Bio,
310 and Apertor Labs.

311 **Table 1.** Selected cases of engineered PKSs used to produce target chemicals in microbial hosts.

312

Organism	Strain	Media	Product	Highest titer	Reference
<i>Escherichia coli</i>	K207-3	Terrific Broth (TB)	Short-chain ketone	4 mg/L	[17]
	K207-3	Luria-Bertani (LB)	Triketide lactone	23 mg/L	[68]
	BAP1	LB	6-deoxyerythronolide B (6-dEB) analog	1 mg/L	[90]
	K207-3	LB	Long side chain triketide lactone	14.6 mg/L	[91]
<i>Synechococcus elongatus</i>	AMC2302	BG11	Multimethyl-branched fatty acid	N/A ^a	[32]
<i>Streptomyces albus</i>	J1074	Modified 042	Short-chain ketone	1 g/L	[12]
<i>Streptomyces coelicolor</i>	OP	SCFM6-2	Triketide lactone	500 mg/L ^b	[92]
	CH999	R2YE	Triketide lactone	3 mg/L	[93]
<i>Streptomyces lividans</i>	K4.114/ K4.115	R5 or R6	6-deoxyerythronolide B (6-dEB) analog	20 mg/L	[94, 95]

<i>Streptomyces venezuelae</i>	ATCC 10712	042	3-Hydroxycarboxylic acid	13.8 mg/L	[64]
	N/A ^a	SCM	Triketide lactone	N/A ^a	[96]
<i>Saccharomyces cerevisiae</i>	BJ5464	YPD	Triketide lactone	1 mg/L	[65]

313

314 ^a not available

315 ^b with diketide feeding

Fig. 3. Heterologous host selection must take into account the genetic tools available for the host as well as the metabolic precursors produced by the host. (A) Promoter/RBS libraries help control transcription and translation levels of heterologous proteins. (B) Appropriate PPTases are needed to adequately phosphopantetheinylate heterologous ACP domains. (C) Malonyl-CoA and methylmalonyl-CoA serve as the most common extender unit precursors for type I PKSs though rare extender units exist. RBS - ribosomal binding site, PPTase - phosphopantetheinyl transferase, CoA-SH - coenzyme A, 3',5'-PAP – 3',5'-phosphoadenosine phosphate.

Fig. 4. DNA synthesis and assembly in new PKS construction. Purple square represents corresponding homology region for yeast assembly and Gibson assembly, or corresponding sticky end for Golden Gate assembly. gDNA - genomic DNA, RBS - ribosome binding site, Loading/Extension/Reduction/Termination - different modules of PKS genes, Linker - linker domains.

343 **Fig. 5.** Proposed methods to troubleshoot the stalled PKS in the host: A) Ppant ejection, B) high
 344 throughput screen/selection. ESI - electrospray ionization, MS - mass spectrometry, CID - collision-
 345 induced dissociation, HCD - higher-energy collisional dissociation, MS/MS - tandem mass
 346 spectrometry.

347

References

1. Sheppard, M.J., A.M. Kunjapur, S.J. Wenck, and K.L.J. Prather (2014) Retro-biosynthetic screening of a modular pathway design achieves selective route for microbial synthesis of 4-methyl-pentanol. *Nat. Commun.* 5: 5031.
2. Birmingham, W.R., C.A. Starbird, T.D. Panosian, D.P. Nannemann, T.M. Iverson, and B.O. Bachmann (2014) Bioretrosynthetic construction of a didanosine biosynthetic pathway. *Nat. Chem. Biol.* 10: 392–399.
3. Donadio, S., M.J. Staver, J.B. McAlpine, S.J. Swanson, and L. Katz (1991) Modular organization of genes required for complex polyketide biosynthesis. *Science* 252: 675–679.
4. Bihlmaier, C., E. Welle, C. Hofmann, K. Welzel, A. Vente, E. Breitling, M. Müller, S. Glaser, and A. Bechthold (2006) Biosynthetic gene cluster for the polyenoyltetramic acid alpha-lipomycin. *Antimicrob. Agents Chemother.* 50: 2113–2121.
5. Jiang, C., H. Wang, Q. Kang, J. Liu, and L. Bai (2012) Cloning and characterization of the polyether salinomycin biosynthesis gene cluster of *Streptomyces albus* XM211. *Appl. Environ. Microbiol.* 78: 994–1003.
6. Weissman, K.J. (2016) Genetic engineering of modular PKSs: from combinatorial biosynthesis to synthetic biology. *Nat. Prod. Rep.* 33: 203–230.
7. Barajas, J. F., J. M. Blake-Hedges, C. B. Bailey, S. Curran, and J. D. Keasling (2017) Engineered polyketides: Synergy between protein and host level engineering. *Synth. Syst. Biotechnol.* 2: 147–166.
8. Yuzawa, S., A. Zargar, B. Pang, L. Katz, and J. D. Keasling (2018) Commodity chemicals from engineered modular type I polyketide synthases. pp. 393–415. In: N. Scrutton (eds.) *Methods in Enzymology: Volume 608, Enzymes in Synthetic Biology*. Academic Press, Cambridge, MA, USA.
9. Klaus, M., and M. Grninger (2018) Engineering strategies for rational polyketide synthase design. *Nat. Prod. Rep.* 35: 1070–1081.
10. Danzon, P., and A. Epstein (2008) Effects of regulation on drug launch and pricing in interdependent markets, National Bureau of Economic Research, Cambridge, MA.

- 376 11. Davis, R., A. Aden, and P.T. Pienkos (2011) Techno-economic analysis of autotrophic
377 microalgae for fuel production. *Appl. Energy* 88: 3524–3531.
- 378 12. Yuzawa, S., M. Mirsiaghi, R. Jovic, T. Fujii, F. Masson, V.T. Benites, E.E.K. Baidoo, E.
379 Sundstrom, D. Tanjore, T.R. Pray, A. George, R.W. Davis, J.M. Gladden, B.A. Simmons, L.
380 Katz, and J.D. Keasling (2018) Short-chain ketone production by engineered polyketide
381 synthases in *Streptomyces albus*. *Nat. Commun.* 9: 4569.
- 382 13. Zargar, A., C.B. Bailey, R.W. Haushalter, C.B. Eiben, L. Katz, and J.D. Keasling (2017)
383 Leveraging microbial biosynthetic pathways for the generation of “drop-in” biofuels. *Curr.*
384 *Opin. Biotechnol.* 45: 156–163.
- 385 14. Keatinge-Clay, A.T., and R.M. Stroud (2006) The structure of a ketoreductase determines the
386 organization of the beta-carbon processing enzymes of modular polyketide synthases. *Structure*
387 14: 737–748.
- 388 15. Akey, D.L., J.R. Razelun, J. Tehranisa, D.H. Sherman, W.H. Gerwick, and J.L. Smith (2010)
389 Crystal structures of dehydratase domains from the curacin polyketide biosynthetic pathway.
390 *Structure* 18: 94–105.
- 391 16. Zheng, J., D.C. Gay, B. Demeler, M.A. White, and A.T. Keatinge-Clay (2012) Divergence of
392 multimodular polyketide synthases revealed by a didomain structure. *Nat. Chem. Biol.* 8: 615–
393 621.
- 394 17. Yuzawa, S., K. Deng, G. Wang, E. E. K. Baidoo, T. R. Northen, P. D. Adams, L. Katz, and J.
395 D. Keasling (2017) Comprehensive in vitro analysis of acyltransferase domain exchanges in
396 modular polyketide synthases and its application for short-chain ketone production. *ACS Synth.*
397 *Biol.* 6: 139–147.
- 398 18. Mo, S., D.H. Kim, J.H. Lee, J.W. Park, D.B. Basnet, Y.H. Ban, Y.J. Yoo, S. Chen, S.R. Park,
399 E.A. Choi, E. Kim, Y.-Y. Jin, S.-K. Lee, J.Y. Park, Y. Liu, M.O. Lee, K.S. Lee, S.J. Kim, D.
400 Kim, B.C. Park, S. Lee, H.J. Kwon, J.-W. Suh, B.S. Moore, S.-K. Lim, and Y.J. Yoon (2011)
401 Biosynthesis of the allylmalonyl-CoA extender unit for the FK506 polyketide synthase
402 proceeds through a dedicated polyketide synthase and facilitates the mutasynthesis of
403 analogues. *J. Am. Chem. Soc.* 133: 976–985.

- 404 19. Garcia-Bernardo, J., L. Xiang, H. Hong, B.S. Moore, and P.F. Leadlay (2004) Engineered
405 biosynthesis of phenyl-substituted polyketides. *Chembiochem* 5: 1129–1131.
- 406 20. Zargar, A., J. F. Barajas, R. Lal, and J. D. Keasling (2018) Polyketide synthases as a platform
407 for chemical product design. *AIChE J.* 64: 4201–4207.
- 408 21. Koryakina, I., C. Kasey, J.B. McArthur, A.N. Lowell, J.A. Chemler, S. Li, D.A. Hansen, D.H.
409 Sherman, and G.J. Williams (2017) Inversion of extender unit selectivity in the erythromycin
410 polyketide synthase by acyltransferase domain engineering. *ACS Chem. Biol.* 12: 114–123.
- 411 22. Eng, C.H., T.W.H. Backman, C.B. Bailey, C. Magnan, H. García Martín, L. Katz, P. Baldi, and
412 J.D. Keasling (2018) ClusterCAD: a computational platform for type I modular polyketide
413 synthase design. *Nucleic Acids Res.* 46: D509–D515.
- 414 23. Blin, K., T. Wolf, M.G. Chevrette, X. Lu, C.J. Schwalen, S.A. Kautsar, H.G. Suarez Duran,
415 E.L.C. de Los Santos, H.U. Kim, M. Nave, J.S. Dickschat, D.A. Mitchell, E. Shelest, R.
416 Breitling, E. Takano, S.Y. Lee, T. Weber, and M.H. Medema (2017) antiSMASH 4.0-
417 improvements in chemistry prediction and gene cluster boundary identification. *Nucleic Acids*
418 *Res.* 45: W36–W41.
- 419 24. Khater, S., M. Gupta, P. Agrawal, N. Sain, J. Prava, P. Gupta, M. Grover, N. Kumar, and D.
420 Mohanty (2017) SBSPKsv2: structure-based sequence analysis of polyketide synthases and
421 non-ribosomal peptide synthetases. *Nucleic Acids Res.* 45: W72–W79.
- 422 25. Conway, K.R., and C.N. Boddy (2013) ClusterMine360: a database of microbial PKS/NRPS
423 biosynthesis. *Nucleic Acids Res.* 41: D402–7.
- 424 26. Stewart, E.J. (2012) Growing unculturable bacteria. *J. Bacteriol.* 194: 4151–4160.
- 425 27. Abdel-Hameed, M., R.L. Bertrand, M.D. Piercey-Normore, and J.L. Sorensen (2016) Putative
426 identification of the usnic acid biosynthetic gene cluster by de novo whole-genome sequencing
427 of a lichen-forming fungus. *Fungal Biol.* 120: 306–316.
- 428 28. van Dissel, D., D. Claessen, M. Roth, and G.P. van Wezel (2015) A novel locus for mycelial
429 aggregation forms a gateway to improved *Streptomyces* cell factories. *Microb. Cell Fact.* 14:
430 44.
- 431 29. Manteca, Á., and P. Yagüe. (2018) *Streptomyces* differentiation in liquid cultures as a trigger of

secondary metabolism. *Antibiotics (Basel)* 7: 41.

30. van Wezel, G.P., P. Krabben, B.A. Traag, B.J.F. Keijser, R. Kerste, E. Vijgenboom, J.J. Heijnen, and B. Kraal (2006) Unlocking *Streptomyces* spp. for use as sustainable industrial production platforms by morphological engineering. *Appl. Environ. Microbiol.* 72: 5283–5288.

31. Ravi, K., J. García-Hidalgo, M.F. Gorwa-Grauslund, and G. Lidén (2017) Conversion of lignin model compounds by *Pseudomonas putida* KT2440 and isolates from compost. *Appl. Microbiol. Biotechnol.* 101: 5059–5070.

32. Roulet, J., A. Taton, J.W. Golden, A. Arabolaza, M.D. Burkart, and H. Gramajo (2018) Development of a cyanobacterial heterologous polyketide production platform. *Metab. Eng.* 49: 94–104.

33. Lee, T.S., R.A. Krupa, F. Zhang, M. Hajimorad, W.J. Holtz, N. Prasad, S.K. Lee, and J.D. Keasling (2011) BglBrick vectors and datasheets: A synthetic biology platform for gene expression. *J. Biol. Eng.* 5: 12.

34. Bai, C., Y. Zhang, X. Zhao, Y. Hu, S. Xiang, J. Miao, C. Lou, and L. Zhang (2015) Exploiting a precise design of universal synthetic modular regulatory elements to unlock the microbial natural products in *Streptomyces*. *Proc. Natl. Acad. Sci. USA* 112: 12181–12186.

35. Flagfeldt, D.B., V. Siewers, L. Huang, and J. Nielsen (2009) Characterization of chromosomal integration sites for heterologous gene expression in *Saccharomyces cerevisiae*. *Yeast* 26: 545–551.

36. Phelan, R.M., D. Sachs, S.J. Petkiewicz, J.F. Barajas, J.M. Blake-Hedges, M.G. Thompson, A. Reider Apel, B.J. Rasor, L. Katz, and J.D. Keasling (2017) Development of next generation synthetic biology tools for use in *Streptomyces venezuelae*. *ACS Synth. Biol.* 6: 159–166.

37. Cobb, R.E., Y. Wang, and H. Zhao (2015) High-efficiency multiplex genome editing of *Streptomyces* species using an engineered CRISPR/Cas system. *ACS Synth. Biol.* 4: 723–728.

38. Tong, Y., P. Charusanti, L. Zhang, T. Weber, and S.Y. Lee (2015) CRISPR-Cas9 Based engineering of *Actinomycetal* genomes. *ACS Synth. Biol.* 4: 1020–1029.

39. Beld, J., E.C. Sonnenschein, C.R. Vickery, J.P. Noel, and M.D. Burkart (2014) The phosphopantetheinyl transferases: catalysis of a post-translational modification crucial for life.

460 *Nat Prod Rep* 31: 61–108.

461 40. Quadri, L.E., P.H. Weinreb, M. Lei, M.M. Nakano, P. Zuber, and C.T. Walsh (1998)

462 Characterization of Sfp, a *Bacillus subtilis* phosphopantetheinyl transferase for peptidyl carrier

463 protein domains in peptide synthetases. *Biochemistry* 37: 1585–1595.

464 41. Kim, J.H., M. Komatsu, K. Shin-Ya, S. Omura, and H. Ikeda (2018) Distribution and functional

465 analysis of the phosphopantetheinyl transferase superfamily in *Actinomycetales*

466 microorganisms. *Proc. Natl. Acad. Sci. USA* 115: 6828–6833.

467 42. Bertrand, R.L., M. Abdel-Hameed, and J.L. Sorensen (2018) Lichen biosynthetic gene clusters.

468 part I. genome sequencing reveals a rich biosynthetic potential. *J. Nat. Prod.* 81: 723–731.

469 43. Dorrestein, P.C., S.B. Bumpus, C.T. Calderone, S. Garneau-Tsodikova, Z.D. Aron, P.D.

470 Straight, R. Kolter, C.T. Walsh, and N.L. Kelleher (2006) Facile detection of acyl and peptidyl

471 intermediates on thiotemplate carrier domains via phosphopantetheinyl elimination reactions

472 during tandem mass spectrometry. *Biochemistry* 45: 12756–12766.

473 44. Fischbach, M.A., and C.T. Walsh (2006) Assembly-line enzymology for polyketide and

474 nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. *Chem. Rev.* 106: 3468–

475 3496.

476 45. Kevany, B.M., D.A. Rasko, and M.G. Thomas (2009) Characterization of the complete

477 zwittermicin A biosynthesis gene cluster from *Bacillus cereus*. *Appl. Environ. Microbiol.* 75:

478 1144–1155.

479 46. Mantovani, S.M., and B.S. Moore (2013) Flavin-linked oxidase catalyzes pyrrolizine formation

480 of dichloropyrrole-containing polyketide extender unit in chlorizidine A. *J. Am. Chem. Soc.*

481 135: 18032–18035.

482 47. Zhu, X., and W. Zhang (2015) Tagging polyketides/non-ribosomal peptides with a clickable

483 functionality and applications. *Front. Chem.* 3: 11.

484 48. Murli, S., J. Kennedy, L.C. Dayem, J.R. Carney, and J.T. Kealey (2003) Metabolic engineering

485 of *Escherichia coli* for improved 6-deoxyerythronolide B production. *J. Ind. Microbiol.*

486 *Biotechnol.* 30: 500–509.

487 49. Smith, D.J., M.K. Burnham, J.H. Bull, J.E. Hodgson, J.M. Ward, P. Browne, J. Brown, B.

488 Barton, A.J. Earl, and G. Turner (1990) Beta-lactam antibiotic biosynthetic genes have been
489 conserved in clusters in prokaryotes and eukaryotes. *EMBO J.* 9: 741–747.

490 50. Zhang, Y., J.P. Muylers, G. Testa, and A.F. Stewart (2000) DNA cloning by homologous
491 recombination in *Escherichia coli*. *Nat. Biotechnol.* 18: 1314–1317.

492 51. van Leeuwen, J., B. Andrews, C. Boone, and G. Tan (2015) Construction of multifragment
493 plasmids by homologous recombination in yeast. *Cold Spring Harb. Protoc.* 2015:
494 pdb.top084111.

495 52. On DNA and Transistors — synthesis.
496 http://www.synthesis.cc/synthesis/2016/03/on_dna_and_transistors.

497 53. Kosuri, S., and G.M. Church (2014) Large-scale de novo DNA synthesis: technologies and
498 applications. *Nat. Methods* 11: 499–507.

499 54. Palluk, S., D.H. Arlow, T. de Rond, S. Barthel, J.S. Kang, R. Bector, H.M. Baghdassarian, A.N.
500 Truong, P.W. Kim, A.K. Singh, N.J. Hillson, and J.D. Keasling (2018) De novo DNA synthesis
501 using polymerase-nucleotide conjugates. *Nat. Biotechnol.* 36: 645–650.

502 55. Ham, T.S., Z. Dmytriv, H. Plahar, J. Chen, N.J. Hillson, and J.D. Keasling (2012) Design,
503 implementation and practice of JBEI-ICE: an open source biological part registry platform and
504 tools. *Nucleic Acids Res.* 40: e141.

505 56. McLaughlin, J.A., C.J. Myers, Z. Zundel, G. Mısırlı, M. Zhang, I.D. Ofiteru, A. Goñi-Moreno,
506 and A. Wipat (2018) SynBioHub: A standards-enabled design repository for synthetic biology.
507 *ACS Synth. Biol.* 7: 682–688.

508 57. Gibson, D.G. (2009) Synthesis of DNA fragments in yeast by one-step assembly of overlapping
509 oligonucleotides. *Nucleic Acids Res.* 37: 6984–6990.

510 58. Gibson, D.G., L. Young, R.-Y. Chuang, J.C. Venter, C.A. Hutchison, and H.O. Smith (2009)
511 Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat. Methods* 6: 343–
512 345.

513 59. Engler, C., R. Kandzia, and S. Marillonnet (2008) A one pot, one step, precision cloning
514 method with high throughput capability. *PLoS One* 3: e3647.

515 60. DeMarini, D.J., C.L. Creasy, Q. Lu, J. Mao, S.A. Sheardown, G.M. Sathe, and G.P. Livi (2001)

516 Oligonucleotide-mediated, PCR-independent cloning by homologous recombination.
517 *BioTechniques* 30: 520–523.

518 61. Liu, G., C. Lanham, J.R. Buchan, and M.E. Kaplan (2017) High-throughput transformation of
519 *Saccharomyces cerevisiae* using liquid handling robots. *PLoS One* 12: e0174128.

520 62. Li, C., G. Florova, K. Akopiants, and K.A. Reynolds (2004) Crotonyl-coenzyme A reductase
521 provides methylmalonyl-CoA precursors for monensin biosynthesis by *Streptomyces*
522 *cinnamomensis* in an oil-based extended fermentation. *Microbiology (Reading, Engl.)* 150:
523 3463–3472.

524 63. Kosa, N.M., T.L. Foley, and M.D. Burkart (2014) Fluorescent techniques for discovery and
525 characterization of phosphopantetheinyl transferase inhibitors. *J. Antibiot.* 67: 113–120.

526 64. Yuzawa, S., C.B. Bailey, T. Fujii, R. Jovic, J.F. Barajas, V.T. Benites, E.E.K. Baidoo, Y. Chen,
527 C.J. Petzold, L. Katz, and J.D. Keasling (2017) Heterologous gene expression of N-terminally
528 truncated variants of LipPksI suggests a functionally critical structural motif in the N-terminus
529 of modular polyketide synthase. *ACS Chem. Biol.* 12: 2725–2729.

530 65. Mutka, S.C., S.M. Bondi, J.R. Carney, N.A. Da Silva, and J.T. Kealey (2006) Metabolic
531 pathway engineering for complex polyketide biosynthesis in *Saccharomyces cerevisiae*. *FEMS*
532 *Yeast Res.* 6: 40–47.

533 66. Pfeifer, B.A., S.J. Admiraal, H. Gramajo, D.E. Cane, and C. Khosla (2001) Biosynthesis of
534 complex polyketides in a metabolically engineered strain of *E. coli*. *Science* 291: 1790–1792.

535 67. Watanabe, K., C.C.C. Wang, C.N. Boddy, D.E. Cane, and C. Khosla (2003) Understanding
536 substrate specificity of polyketide synthase modules by generating hybrid multimodular
537 synthases. *J. Biol. Chem.* 278: 42020–42026.

538 68. Menzella, H.G., R. Reid, J.R. Carney, S.S. Chandran, S.J. Reisinger, K.G. Patel, D.A.
539 Hopwood, and D.V. Santi (2005) Combinatorial polyketide biosynthesis by de novo design and
540 rearrangement of modular polyketide synthase genes. *Nat. Biotechnol.* 23: 1171–1176.

541 69. Bibb, M.J. (2005) Regulation of secondary metabolism in *Streptomyces*. *Curr. Opin.*
542 *Microbiol.* 8: 208–215.

543 70. Rateb, M.E., Z. Yu, Y. Yan, D. Yang, T. Huang, S. Vodanovic-Jankovic, M.A. Kron, and B.

544 Shen (2014) Medium optimization of *Streptomyces* sp. 17944 for tirandamycin B production
545 and isolation and structural elucidation of tirandamycins H, I and J. *J. Antibiot.* 67: 127–132.

546 71. Singh, V., S. Haque, R. Niwas, A. Srivastava, M. Pasupuleti, and C.K.M. Tripathi (2016)
547 Strategies for fermentation medium optimization: An in-depth review. *Front. Microbiol.* 7:
548 2087.

549 72. Costello, Z., and H.G. Martin (2018) A machine learning approach to predict metabolic
550 pathway dynamics from time-series multiomics data. *npj Syst. Biol. Appl.* 4: 19.

551 73. Poust, S., A. Hagen, L. Katz, and J.D. Keasling (2014) Narrowing the gap between the promise
552 and reality of polyketide synthases as a synthetic biology platform. *Curr. Opin. Biotechnol.* 30:
553 32–39.

554 74. Hagen, A., S. Poust, T. de Rond, J.L. Fortman, L. Katz, C.J. Petzold, and J.D. Keasling (2016)
555 Engineering a polyketide synthase for in vitro production of adipic acid. *ACS Synth. Biol.* 5:
556 21–27.

557 75. Qu, X., C. Lei, and W. Liu (2011) Transcriptome mining of active biosynthetic pathways and
558 their associated products in *Streptomyces flaveolus*. *Angew. Chem. Int. Ed. Engl.* 50: 9651–
559 9654.

560 76. Bumpus, S.B., B.S. Evans, P.M. Thomas, I. Ntai, and N.L. Kelleher (2009) A proteomics
561 approach to discovering natural products and their biosynthetic pathways. *Nat. Biotechnol.* 27:
562 951–956.

563 77. Packer, M.S., and D.R. Liu (2015) Methods for the directed evolution of proteins. *Nat. Rev.*
564 *Genet.* 16: 379–394.

565 78. Chemler, J.A., A. Tripathi, D.A. Hansen, M. O’Neil-Johnson, R.B. Williams, C. Starks, S.R.
566 Park, and D.H. Sherman (2015) Evolution of efficient modular polyketide synthases by
567 homologous recombination. *J. Am. Chem. Soc.* 137: 10603–10609.

568 79. Veach, B.T., T.K. Mudalige, and P. Rye (2017) RapidFire mass spectrometry with enhanced
569 throughput as an alternative to liquid-liquid salt assisted extraction and LC/MS analysis for
570 sulfonamides in honey. *Anal. Chem.* 89: 3256–3260.

571 80. Gao, X., X. Xie, I. Pashkov, M.R. Sawaya, J. Laidman, W. Zhang, R. Cacho, T.O. Yeates, and

572 Y. Tang (2009) Directed evolution and structural characterization of a simvastatin synthase.
573 *Chem. Biol.* 16: 1064–1074.

574 81. Dietrich, J.A., D.L. Shis, A. Alikhani, and J.D. Keasling (2013) Transcription factor-based
575 screens and synthetic selections for microbial small-molecule biosynthesis. *ACS Synth. Biol.* 2:
576 47–58.

577 82. Barajas, J.F., A. Zargar, B. Pang, V.T. Benites, J. Gin, E.E.K. Baidoo, C.J. Petzold, N.J.
578 Hillson, and J.D. Keasling (2018) Biochemical Characterization of β -Amino Acid
579 Incorporation in Fluvirucin B2 Biosynthesis. *Chembiochem* 19: 1391–1395.

580 83. Zhang, J., J.F. Barajas, M. Burdu, T.L. Ruegg, B. Dias, and J.D. Keasling (2017) Development
581 of a transcription factor-based lactam biosensor. *ACS Synth. Biol.* 6: 439–445.

582 84. Yeom, S.-J., M. Kim, K.K. Kwon, Y. Fu, E. Rha, S.-H. Park, H. Lee, H. Kim, D.-H. Lee, D.-M.
583 Kim, and S.-G. Lee (2018) A synthetic microbial biosensor for high-throughput screening of
584 lactam biocatalysts. *Nat. Commun.* 9: 5053.

585 85. Tang, S.-Y., S. Qian, O. Akinterinwa, C.S. Frei, J.A. Gredell, and P.C. Cirino (2013) Screening
586 for enhanced triacetic acid lactone production by recombinant *Escherichia coli* expressing a
587 designed triacetic acid lactone reporter. *J. Am. Chem. Soc.* 135: 10099–10103.

588 86. Hughes, A.J., J.F. Detelich, and A.T. Keatinge-Clay (2012) Employing a polyketide synthase
589 module and thioesterase in the semipreparative biocatalysis of diverse triketide pyrones.
590 *Medchemcomm* 3: 956.

591 87. Dejong, C.A., G.M. Chen, H. Li, C.W. Johnston, M.R. Edwards, P.N. Rees, M.A. Skinnider,
592 A.L.H. Webster, and N.A. Magarvey (2016) Polyketide and nonribosomal peptide retro-
593 biosynthesis and global gene cluster matching. *Nat. Chem. Biol.* 12: 1007–1014.

594 88. Osswald, C., G. Zipf, G. Schmidt, J. Maier, H.S. Bernauer, R. Müller, and S.C. Wenzel (2014)
595 Modular construction of a functional artificial epothilone polyketide pathway. *ACS Synth. Biol.*
596 3: 759–772.

597 89. Myronovskyi, M., B. Rosenkränzer, S. Nadmid, P. Pujic, P. Normand, and A. Luzhetskyy
598 (2018) Generation of a cluster-free *Streptomyces albus* chassis strains for improved
599 heterologous expression of secondary metabolite clusters. *Metab. Eng.* 49: 316–324.

- 600 90. Lee, H.Y., C.J.B. Harvey, D.E. Cane, and C. Khosla (2011) Improved precursor-directed
601 biosynthesis in *E. coli* via directed evolution. *J. Antibiot.* 64: 59–64.
- 602 91. Menzella, H.G., J.R. Carney, and D.V. Santi (2007) Rational design and assembly of synthetic
603 trimodular polyketide synthases. *Chem. Biol.* 14: 143–151.
- 604 92. Regentin, R., J. Kennedy, N. Wu, J.R. Carney, P. Licari, J. Galazzo, and R. Desai (2004)
605 Precursor-directed biosynthesis of novel triketide lactones. *Biotechnol. Prog.* 20: 122–127.
- 606 93. Kao, C.M., L. Katz, and C. Khosla (1994) Engineered biosynthesis of a complete macrolactone
607 in a heterologous host. *Science* 265: 509–512.
- 608 94. Xue, Q., G. Ashley, C.R. Hutchinson, and D.V. Santi (1999) A multiplasmid approach to
609 preparing large libraries of polyketides. *Proc. Natl. Acad. Sci. USA* 96: 11740–11745.
- 610 95. Kato, Y., L. Bai, Q. Xue, W.P. Revill, T.-W. Yu, and H.G. Floss (2002) Functional expression
611 of genes involved in the biosynthesis of the novel polyketide chain extension unit,
612 methoxymalonyl-acyl carrier protein, and engineered biosynthesis of 2-desmethyl-2-methoxy-
613 6-deoxyerythronolide B. *J. Am. Chem. Soc.* 124: 5268–5269.
- 614 96. Yan, J., C. Hazzard, S.A. Bonnett, and K.A. Reynolds (2012) Functional modular dissection of
615 DEBS1-TE changes triketide lactone ratios and provides insight into acyl group loading,
616 hydrolysis, and ACP transfer. *Biochemistry* 51: 9333–9341.